Beispiel: Heart Attack

Suchen Sie in klinischen Studien nach: Dasatinib

Insgesamt 333 ergebnisse

NCT03216070

Unbekannter Status

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Bedingungen: Chronic Myelogenous Leukemia
NCT04115059

Rekrutierung

Dasatinib In Waldenström Macroglobulinemia

Bedingungen: Waldenstrom Macroglobulinemia; DASATINIB
NCT04155411

Rekrutierung

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Bedingungen: Dasatinib; BCR-ABL; Chronic Myeloid Leukemia
NCT01724879

Abgeschlossen

Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

Bedingungen: Philadelphia Positive Acute Lymphoblastic Leukemia
NCT03625388

Rekrutierung

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Bedingungen: Chronic Myelogenous Leukemia
NCT04439305

Zurückgezogen

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Bedingungen: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT01609816

Beendet

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Bedingungen: Non-Hodgkin's Lymphoma; Multiple; Mycosis Fungoides; Hodgkin's Lymphoma; Multiple Myeloma
NCT01051115

Unbekannter Status

Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

Bedingungen: Chronic Lymphocytic Leukemia
NCT03560908

Zurückgezogen

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Bedingungen: Relapsed AML; T(8;21); C-KIT Mutation
NCT03193281

Rekrutierung

KISS Study: Kinase Inhibition With Sprycel Start up

Bedingungen: Chronic Myeloid Leukemia
NCT02268370

Aktiv, nicht rekrutierend

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Bedingungen: Chronic Myeloid Leukemia
NCT02428855

Abgeschlossen

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Bedingungen: Cholangiocarcinoma
NCT02389972

Abgeschlossen

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Bedingungen: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NCT01850004

Aktiv, nicht rekrutierend

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Bedingungen: Chronic Phase Chronic Myeloid Leukemia
NCT01491633

Beendet

Dasatinib in Advanced Squamous Cell Lung Cancer

Bedingungen: Squamous Cell Lung Cancer
NCT00858403

Beendet

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Bedingungen: Lung Cancer
NCT00429949

Abgeschlossen

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Bedingungen: Relapsed, Refractory or Plateau Phase Multiple Myeloma
NCT00700882

Abgeschlossen

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Bedingungen: Melanoma (Skin)
NCT00624585

Abgeschlossen

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Bedingungen: Myelodysplastic Syndromes
NCT01643603

Beendet

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Bedingungen: Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Myeloid Leukemia; Multiple Myeloma; Myelodysplastic Syndrome; Lymphoid Leukemia
NCT00652574

Unbekannter Status

Dasatinib in Resectable Malignant Pleural Mesothelioma

Bedingungen: Malignant Pleural Mesothelioma
NCT04603872

Rekrutierung

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Bedingungen: Multiple Myeloma in Relapse; Multiple Myeloma, Refractory; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphocytic Leukaemia Refractory; Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory
NCT01342679

Abgeschlossen

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Bedingungen: Chronic Myeloid Leukemia
NCT01310010

Unbekannter Status

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

Bedingungen: Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
NCT00787267

Beendet

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Bedingungen: Non Small Cell Lung Cancer